A Randomized Open-Label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 [remogliflozin etabonate] on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs Metformin; Remogliflozin etabonate
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 09 Jun 2009 This study was published as an abstract in the proceedings of the 69th Annual Scientific Sessions of the American Diabetes Association.
- 17 Apr 2008 Status changed from in progress to completed.
- 01 Nov 2006 New trial record.